Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-06-14
2009-11-24
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S141100, C424S155100
Reexamination Certificate
active
07622115
ABSTRACT:
This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
REFERENCES:
patent: 5036003 (1991-07-01), Olander et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 6582959 (2003-06-01), Kim
patent: 6884879 (2005-04-01), Baca et al.
patent: 7060269 (2006-06-01), Baca et al.
patent: 7169901 (2007-01-01), Baca et al.
patent: 7227004 (2007-06-01), Kim
patent: 7297334 (2007-11-01), Baca et al.
patent: 7365166 (2008-04-01), Baca et al.
patent: 7375193 (2008-05-01), Baca et al.
patent: 7482005 (2009-01-01), Kim
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 2002/0098187 (2002-07-01), Ferrara et al.
patent: 2003/0023046 (2003-01-01), Ferrara et al.
patent: 2004/0122018 (2004-06-01), Zhu et al.
patent: 2005/0053599 (2005-03-01), Van Bruggen et al.
patent: 2005/0186208 (2005-08-01), Fyfe et al.
patent: 2005/0244405 (2005-11-01), Van Bruggen et al.
patent: 2006/0193862 (2006-08-01), Ferrara et al.
patent: 2007/0025999 (2007-02-01), Fyfe et al.
patent: 2007/0031413 (2007-02-01), Fyfe et al.
patent: 2007/0036753 (2007-02-01), Fyfe et al.
patent: 2007/0036754 (2007-02-01), Fyfe et al.
patent: 2007/0036755 (2007-02-01), Fyfe et al.
patent: 2007/0036790 (2007-02-01), Fyfe et al.
patent: 2007/0059302 (2007-03-01), Baca et al.
patent: 2007/0071718 (2007-03-01), Fyfe et al.
patent: 2007/0071748 (2007-03-01), Fyfe et al.
patent: 2007/0071749 (2007-03-01), Fyfe et al.
patent: 2007/0110755 (2007-05-01), Ferrara et al.
patent: 2007/0148177 (2007-06-01), Fyfe et al.
patent: 2007/0148178 (2007-06-01), Fyfe et al.
patent: 2007/0154483 (2007-07-01), Fyfe et al.
patent: 2007/0160608 (2007-07-01), Fyfe et al.
patent: 2007/0196374 (2007-08-01), Baca et al.
patent: 2007/0253959 (2007-11-01), Ferrara et al.
patent: 2007/0258980 (2007-11-01), Van Bruggen et al.
patent: 2008/0160029 (2008-07-01), Fyfe et al.
patent: 2008/0166351 (2008-07-01), Fyfe et al.
patent: 2008/0181900 (2008-07-01), Ferrara et al.
patent: 2008/0187534 (2008-08-01), Baca et al.
patent: 2008/0226629 (2008-09-01), Baca et al.
patent: 2008/0241148 (2008-10-01), Fyfe et al.
patent: 2008/0248036 (2008-10-01), Fyfe et al.
patent: 2008/0248049 (2008-10-01), Fyfe et al.
patent: 2008/0267968 (2008-10-01), Fyfe et al.
patent: 2008/0279860 (2008-11-01), Fyfe et al.
patent: 2008/0292630 (2008-11-01), Fyfe et al.
patent: 2008/0292631 (2008-11-01), Fyfe et al.
patent: 2008/0299116 (2008-12-01), Van Bruggen et al.
patent: 2008/0311118 (2008-12-01), Van Bruggen et al.
patent: 2009/0010881 (2009-01-01), Fyfe et al.
patent: 2009/0010883 (2009-01-01), Fyfe et al.
patent: 2009/0053216 (2009-02-01), Fyfe et al.
patent: 2009/0081232 (2009-03-01), Kim
patent: 1445242 (2003-10-01), None
patent: 0 666 868 (2002-04-01), None
patent: 10114680 (1998-06-01), None
patent: 2 177 349 (2001-12-01), None
patent: 2177349 (2001-12-01), None
patent: WO 92/14748 (1992-03-01), None
patent: 98/45331 (1998-10-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 2007/107329 (2007-09-01), None
Gordon et al (J of Clinical Oncology, Feb. 2001, 19:843-850, IDS).
US News & World Report.com, Dec. 10, 2008, 2 pages.
Braun et al., “New Systemic Frontline Treatment for Metastatic Colorectal Carcinoma”Cancer100:1558-1577 (2004).
D'Orazio et al., “Adding a Humanized Antibody to Vascular Endothelial Growth Factor (Bevacizumab, Avastin™) to Chemotherapy Improves Survival in Metastatic Colorectal Cancer”Clinical Colorectal Cancer3:85-88 (2003).
de Gramont et al., “Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer”Journal of Clinical Oncology18:2938-2947 (2000).
Douillard et al., “Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial”Lancet355:1041-1047 (2000).
Fernando and Hurwitz, “Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab”The Oncologist9(suppl 1):11-18 (2004).
Ferrara et al., “Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer”Nature Reviews-Drug Discovery3:391-400 (May 2004).
Goldberg at al., “A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer”Journal of Clinical Oncology22:23-30 (2004.
Hejna et al., “Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer”Anti-Cancer Drugs11:629-34 (2000).
Hurwitz et al., “Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in . . .”ASCO American Society of Clinical Oncology (www.asco.org/hurwitz—no3646) Abstract No. 3646 (May 2003).
Hurwitz et al., “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer”N. Engl J Med350(23):2335-2342 (Jun. 23, 2004).
Kabbinavar et al., “Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU) /Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer”Journal of Clinical Oncology21(1):60-65 (Jan. 1, 2003).
Margolin K, et al., “Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data”J Clin Oncol19:851-856 (2001).
Saltz et al., “Irinotecan Plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer”New England J. of Medicine343:905-914 (2000).
Yang et al., “Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy”Cancer Research59:1236-1243 (Mar. 15, 1999).
Folkman, Judah, “Angiogenesis in cancer, vascular, rheumatoid and other disease”Nature Medicine1:27-31 (1995).
Jain, Rakesh K., “Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy”Science307:58-62 (2005).
Joo et al., “Cyclooxygenase-2 Overexpression Correlates With Vascular Endothelial Growth Factor Expression and Tumor Angiogenesis in Gastric Cancer”J. Clin. Gastroenterol37:28-33 (2003).
Avastin® Product Label, May 2009.
Burstein HJ, et al., “Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer”Breast Cancer Res Treat76:S115 (2002).
Folkman, J, “Anti-angiogenesis Agents”Cancer Principles&Practice of Oncology(Chapter 63), 7th Edition edition pp. 2865-2882 (2005).
Fountzilas et al., “Paclitaxel and Carboplatin as First-Line Chemotherapy for Advanced Breast Cancer”Oncology(Supplement No. 1) pp. 45-48 (Jan. 1998).
Friedman et al, “Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma”Journal of Clinical Oncology17(5):1516-1525 (May 1999).
Giles et al., “Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia”Journal of Clinical Oncology20(3):656-664 (Feb. 1, 2002).
Gossmann et al, “Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Marker of Tumor Response to Anti-Angiogenic Therapy in a Xenograft Model of Glioblastoma Multiforme”J. of Magnetic Resonance Imaging15:233-240 (2002) .
Herbst at al., “Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers”Semin Oncol. 29 (1 Suppl 4):27-36 (Feb. 2002).
Herbst, “Targeted Therapy
Fyfe Gwendolyn
Holmgren Eric
Mass Robert D.
Novotny William
Genentech Inc.
Goddard Laura B
LandOfFree
Treatment with anti-VEGF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment with anti-VEGF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment with anti-VEGF antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4080826